At the news
? MIXEDIMPACT 6/10 8-K filed Apr 17, 2026 at 16:30 ET
Pliant Therapeutics announced the retirement of three board members effective at the 2026 Annual Meeting and a broad stock option repricing to $1.33 per share for employees, including executives, to retain talent during a critical phase. The repricing is contingent on continued service through a defined retention period.
- Three independent directors, David E.I. Pyott, Katharine Knobil, M.D., and Suzanne Bruhn, Ph.D., notified the company of their retirement from the board and all committees, effective at the 2026 Annual Meeting.
- The board approved a stock option repricing for all employee-held options granted on or before March 1, 2025, including those held by executive officers.
- The new exercise price is $1.33 per share, the closing price on the effective date (April 17, 2026), down from higher underwater prices.
- Eligible participants, including the CEO, CFO, CHRO, and COO, must remain employed through a retention period (12 or 18 months) to benefit from the repricing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access